New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
11:57 EDTKERXKeryx options active on wide price movement
Keryx February 8 and March 9 calls are active on total call volume of 14K contracts (10K puts). February call option implied volatility is at of 127, March is at 100; compared to its 26-week average of 110 according to Track Data, Active option volume suggests traders taking positions for larger price movement.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
09:42 EDTKERXBattleground: Will this $5 biotech stock go to $22 or $1.50?
In the last two days, analysts have issued widely divergent opinions and price targets on Keryx Biopharmaceuticals, a small-cap biotech company focused on the treatment of renal diseases. CITI SAYS SELL: Citi analyst Yigal Nochomovitz started shares of Keryx yesterday with a Sell rating and $1.50 price target. Nochomovitz expects the Auryxia launch and long-term sales trends to "materially underperform" consensus expectations. Auryxia is a phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Nochomovitz estimates Auryxia has peak U.S. sales potential of $57M, well below the consensus estimate of $485M. BREAN SAYS BUY: Brean Capital analyst Jonathan Aschoff told investors this morning that he views the recent selloff in shares of Keryx as overdone. The bearish assessment of Auryxia's ultimate market potential is premature, Aschoff contends. Auryxia "finally achieved" a majority of insurance coverage in early August, which will facilitate prescription writing, the analyst argues. He also believes Keryx's 50% salesforce increase should make a "noticeable impact" on revenue. Aschoff reiterated a Buy rating on the stock with a $22 price target. WHAT'S NOTABLE: Along with yesterday's note on Keryx, Nochomovitz expanded Citi's coverage of the Biotech space by initiating seven other small- and mid-cap names. Chimerix (CMRX) is Nochomovitz's top pick with a Buy rating and $80 price target. Other stocks to which he assigned Buy ratings include Ophthotech (OPHT), Relypsa (RLYP) and ZS Pharma (ZSPH). In addition to placing a Sell rating on Keryx, Nochomovitz started Ultragenyx (RARE) with a sell and an $87 price target. He rounded out his coverage with Neutral ratings on Medivation (MDVN) and Puma Biotechnology (PBYI). PRICE ACTION: In early trading, Keryx shares fell 40c, or 7,9%, to $4.66, which comes on top of the 16% decline the stock suffered yesterday. Over the last three months, Keryx shares have fallen more than 50%.
06:17 EDTKERXKeryx recent selloff overdone, says Brean Capital
Subscribe for More Information
September 3, 2015
12:23 EDTKERXOn The Fly: Top stock stories at midday
Subscribe for More Information
08:15 EDTKERXChimerix rallies, Keryx falls after Citi expands Biotech coverage
Subscribe for More Information
06:39 EDTKERXKeryx initiated with a Sell, $1.50 price target at Citi
Citi analyst Yigal Nochomovitz started shares of Keryx Biopharmaceuticals (KERX) with a Sell rating and $1.50 price target. The stock closed yesterday up 18c to $6.03. Nochomovitz expects the Auryxia launch and long-term sales trends to "materially underperform" consensus expectations. Auryxia is a phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Nochomovitz estimates Auryxia has peak U.S. sales potential of $57M, well below the consensus estimate of $485M. He named Chimerix (CMRX) his top pick in the small- and mid-cap biotech space. The analyst initiated the name this morning with a Buy rating and $80 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use